Alzheimer's Disease Market Positioned for Accelerated Expansion with a CAGR of 23.7% Through 2034, DelveInsight Finds

The Alzheimer's Disease market was valued at approximately USD 5 billion in 2025 and is projected to grow at a robust CAGR of 23.7% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Alzheimer's Disease landscape. By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Alzheimer's Disease market is increasingly guided by disease-modifying therapies (DMTs) targeting amyloid-beta and phosphorylated tau pathology. Anti-amyloid monoclonal antibodies represent a highly lucrative segment, with treatments like LEQEMBI (lecanemab) and KISUNLA (donanemab) leading the immunotherapy landscape. These breakthrough therapies are generating significant market momentum and establishing new standards in early-stage AD treatment.

Alzheimer's Disease Overview

Alzheimer's Disease is a progressive neurodegenerative brain disorder that represents the most common cause of dementia, accounting for approximately 60–70% of all dementia cases globally. The disease is characterized by the accumulation of amyloid-beta plaques and phosphorylated tau tangles in the brain, leading to neuronal degeneration and progressive cognitive decline. Alzheimer's Disease typically begins with mild cognitive impairment (MCI), progresses through mild and moderate dementia stages, and ultimately results in severe cognitive and functional deterioration. Early detection and personalized treatment approaches using disease-modifying therapies are transforming the therapeutic landscape, offering the potential to slow disease progression and preserve cognitive function in patients with early-stage disease.

Alzheimer's Disease Epidemiology

The Alzheimer's Disease epidemiological analysis provides a comprehensive view of the disease's prevalence, incidence, and patient demographics across key regions. Approximately 15 million people were diagnosed with Alzheimer's Disease across 7MM in 2024. The United States represented the largest number of these diagnosed cases. Furthermore, the prevalence demonstrates marked gender variations, with women accounting for higher proportions due to greater longevity. Prevalence rates increase exponentially with age. Japan also exhibits a high prevalence rate among major pharmaceutical markets.

These epidemiological trends underscore the substantial disease burden globally and the urgent need for effective disease-modifying therapies across all major pharmaceutical markets.

Alzheimer's Disease Epidemiology Segmentation

The Alzheimer's Disease market report provides epidemiological analysis for the study period 2020–2034 in the 7MM (seven major markets: The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan) segmented into:

• Total Diagnosed Prevalent Cases of Alzheimer’s Disease
• Gender-specific Diagnosed Prevalent Cases of Alzheimer’s Disease
• Age-specific Diagnosed Prevalent Cases of Alzheimer’s Disease
• Severity-specific Diagnosed Prevalent Cases of Alzheimer’s Disease
• Diagnosed Prevalent Cases of Agitation in Alzheimer’s Disease
• Diagnosed Prevalent Cases of Psychosis in Alzheimer’s Disease

Download the Alzheimer's Disease Market report to understand which factors are driving Alzheimer's Disease epidemiology trends and disease burden projections across different regions.

Recent Developments in the Alzheimer's Disease Treatment Landscape

• January 2025: The FDA approved Eisai and Biogen's Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), allowing for once-monthly maintenance dosing in patients with early-stage Alzheimer's Disease. This approval offers a more convenient alternative to biweekly dosing after an 18-month initiation phase, helping maintain clinical benefits while reducing treatment burden and improving patient adherence.
• January 2025: The FDA accepted a Biologics License Application (BLA) for the LEQEMBI subcutaneous autoinjector (SC-AI), a more convenient weekly maintenance dosing option for patients with early Alzheimer's Disease. This innovation, developed by BioArctic AB and Eisai, aims to enhance patient adherence and accessibility in clinical practice.
• January 2025: The FDA granted Fast Track designation to posdinemab, a monoclonal antibody targeting phosphorylated tau, under investigation in the Phase 2b AuTonomy study for early Alzheimer's Disease treatment. This designation accelerates the development pathway for this novel tau-directed immunotherapy.
• July 2025: Data presented at the 2025 Alzheimer's Association International Conference (AAIC) revealed that Eli Lilly's KISUNLA (donanemab-azbt) reduces the risk of disease progression by 27% when administered early in Alzheimer's Disease. The cognitive benefits of Kisunla appeared to increase over time, with patients experiencing a decline of 1.2 points after three years compared to a 0.6 point decrease at 18 months, as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB) score. Over 75% of patients treated with Kisunla achieved amyloid clearance within the 18-month period.
• July 2025: Long-term findings from the Phase III Clarity AD trial indicated that LEQEMBI (lecanemab) reduced CDR-SB scores by up to 1.75 points over four years when compared to patients in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. This represented a significant improvement from the three-year CDR-SB score of 1.01 points, demonstrating sustained cognitive benefits of anti-amyloid therapy over extended treatment periods.
• July 2024: The FDA approved KISUNLA (donanemab-azbt), developed by Eli Lilly, marking a major regulatory milestone in Alzheimer's Disease treatment. This anti-amyloid monoclonal antibody targets amyloid-beta plaques and is indicated for patients with mild cognitive impairment or mild dementia stage of early AD with confirmed amyloid pathology.
• July 2024: FDA approval of an updated label for donanemab included a new recommended titration dosing schedule aimed at reducing amyloid-related imaging abnormalities (ARIA) risk while maintaining efficacy. Data from the TRAILBLAZER-ALZ 6 study demonstrated that the modified titration arm achieved an ARIA-E frequency of 13.7% compared with 23.7% in the standard arm at 24 weeks.
• Ongoing clinical trials: Multiple Phase 2 and Phase 3 trials are assessing novel disease-modifying therapies targeting various pathogenic mechanisms including amyloid-beta, phosphorylated tau, neuroinflammation, and synaptic dysfunction.

Alzheimer's Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section of the report focuses on the rate of adoption of recently launched or expected-to-be-launched Alzheimer's Disease therapies during the forecast period. The analysis covers Alzheimer's Disease market uptake by drugs, patient uptake by therapies, and sales forecasting for each therapy.

The therapeutics assessment section helps identify drugs with the most rapid uptake and the reasons behind maximal utilization of specific treatments. Additionally, it compares therapies based on projected market share. The report covers the Alzheimer's Disease Pipeline Development Activities, providing valuable insights about different therapeutic candidates in various stages of development and the key companies involved in advancing targeted therapeutics. It analyzes recent developments, including collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information for emerging therapies.

Alzheimer's Disease Therapies and Key Companies

• LEQEMBI (lecanemab-irmb): Eisai and Biogen
• KISUNLA (donanemab-azbt): Eli Lilly
• ANAVEX 2-73 (blarcamesine): Anavex Life Sciences
• GLP-1 agonists (Semaglutide): Roche/Genentech
• AXS-05 (dextromethorphan and bupropion): Axsome Therapeutics
• ADUCANUMAB (aduhelm): Biogen
• REMTERNETUG: Anti-amyloid agent targeting pyroglutamate plaques
• Solanezumab: Anti-amyloid agent targeting monomeric amyloid proteins
• Posdinemab: Monoclonal antibody targeting phosphorylated tau
• Various neuroprotective agents targeting inflammation, synaptic health, and neuroplasticity

Key companies driving innovation in the Alzheimer's Disease market include Eisai, BioArctic AB, Biogen, Hoffmann-La Roche/Chugai, Anavex Life Sciences, AbbVie, Eli Lilly, and Axsome Therapeutics, among others. Know the competitive advantages of these companies @ Alzheimer's Disease Competitive Landscape

Alzheimer's Disease Market Drivers

• Increasing prevalence of Alzheimer's Disease globally due to aging populations and increasing life expectancy
• Rapid aging of baby boomer generation and rising geriatric population in developed and emerging markets
• Growing awareness and improved diagnosis of early-stage Alzheimer's Disease and mild cognitive impairment
• Advancement of molecular diagnostics and biomarker testing enabling early detection and risk stratification
• Development of disease-modifying therapies that target underlying pathogenic mechanisms rather than just symptomatic relief
• Recent FDA approvals of anti-amyloid monoclonal antibodies establishing new therapeutic paradigms
• Increasing healthcare expenditure and government initiatives supporting neurodegenerative disease research and care
• Rising demand for personalized medicine approaches based on amyloid and tau biomarker status
• Expansion of clinical trial networks and improved patient recruitment strategies
• Digital health integration including AI-driven diagnostics, telemedicine, and remote cognitive monitoring

Alzheimer's Disease Market Barriers

• High cost of disease-modifying therapies limiting patient access and affordability, particularly in developing nations
• Complex diagnostic requirements including advanced imaging (PET, MRI) and biomarker testing not universally available
• Challenges associated with amyloid-related imaging abnormalities (ARIA) including amyloid-related imaging abnormalities-edema (ARIA-E) and microhemorrhages (ARIA-M)
• Limited awareness of early-stage disease diagnosis and treatment in primary care settings
• Heterogeneity of Alzheimer's Disease pathology requiring individualized treatment approaches
• Long and complex regulatory approval processes for novel therapeutics
• Variable patient responses and disease progression trajectories across populations
• Limited reimbursement coverage and insurance barriers in certain markets
• Safety and tolerability concerns associated with anti-amyloid immunotherapy
• Variability in genetic and environmental factors influencing disease risk and treatment response

For for an indepth understanding of Alzheimer's Disease market dynamics, its drivers and barriers, you can download the report @ Alzheimer's Disease Market Report

Scope of the Alzheimer's Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM (The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan)
• Key Alzheimer's Disease Companies: Eisai, BioArctic AB, Biogen, Hoffmann-La Roche/Chugai, Anavex Life Sciences, AbbVie, Eli Lilly, Axsome Therapeutics, and others
• Key Alzheimer's Disease Therapies: LEQEMBI (lecanemab), KISUNLA (donanemab), ANAVEX 2-73 (blarcamesine), AXS-05, GLP-1 agonists, and emerging pipeline candidates
• Alzheimer's Disease Therapeutic Assessment: Current marketed therapies and emerging therapies in development
• Alzheimer's Disease Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, market entry strategies
• Alzheimer's Disease Unmet Needs, Key Opinion Leaders' views, Analyst perspectives, Market Access and Reimbursement